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ABSTRACT 
Nowadays, the patient safety is seriously jeopardized by the emergence and spread of nosocomial pathogens in the form 
of biofilm that is resistant to traditional and affordable antimicrobials. Although advances in organic synthesis have 
extended the lifetime of classic antibiotics through synthetic modifications, the search of innovative antibiofilm 
compounds from natural sources can provide new templates, novel targets and unique mechanisms that should have 
advantages over known antimicrobial agents. Testing sub-lethal concentrations of crude extracts and/or isolated 
compounds from plants and microorganisms is critical to acting on mechanisms subtler than the killing activity, e.g. 
those influencing the multicellular behavior, offering an elegant way to develop novel antimicrobial-free antibiofilm 
strategies. 
Herein we discussed the search and biological activity of small molecules from natural sources and their synthetic 
derivatives able to modulate biofilm genesis of nosocomial pathogens through non-microbicidal mechanisms (sub-lethal 
concentrations). The present work offers an overview about the approaches applied to the discovery of lead small 
molecules including i) conventional drug design methods like screening of chemical compounds obtained from nature 
and ii) computer-aided drug design approaches. Finally, a classification (not exhaustive but representative) based on the 
natural origin of small molecules and their synthetic derivatives was reported.  
The information presented in this review should be of interest to a broad range of disciplines and represents an effort to 
summarize experimental research and advances in this field. 
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INTRODUCTION 
With Fleming's discovery of the penicillin in 1929, and Domagk's discovery in 1935 of synthetic chemicals 
(sulfonamides), the 20th century opened with the promise of the eradication of most infectious diseases in global host 
populations. At present, it is becoming more and more evident that the last century closed with the specter of re-
emergence of many deadly infectious diseases as the miracle of the antimicrobial chemotherapy has been eroded by the 
emergence and increasing prevalence of microbial strains in form of biofilm that are resistant to available treatments. 
This is readily seen in the continuous escalation of healthcare-associated infections (formally called nosocomial 
infections) at an alarming rate. In American hospitals alone, nosocomial infections account for an estimated 1.7 million 
infections and 99,000 associated deaths each year [1]. The European Centre for Disease Prevention and Control 
(ECDC) declared that every year approximately 4.1 million people in EU Countries catch an infectious disease 
associated with healthcare system and that around 40,000 die as direct consequence of these infections [2]. 
Well-known clinical examples of recalcitrant nosocomial infections include Pseudomonas aeruginosa that is 
responsible for many infections including those associated with ventilator-associated pneumonia, bacterial keratitis, 
otitis, burns, ischemic osteomyelitis and lungs of patients with cystic fibrosis, and Escherichia coli that causes urinary 
and gastrointestinal tract infections and septicemia [3-5]. Acinetobacter baumannii is an opportunistic pathogen able to 
persist in the hospital environment allowing contact with susceptible patients and causing outbreaks of ventilator-
associated pneumonia, meningitis, bacteremia, and urinary tract and wound infections [6]. Important etiologic agents of 
systemic and nosocomial infections have been detected in the microbiota of subgingival biofilm, including the causative 
agents of periodontitis and caries like Streptococcus spp., Lactobacillus spp., and Candida albicans [7]. Furthermore, 
tuberculous granulomas that contain latent Mycobacterium tuberculosis and Staphylococcus aureus in chronic wounds 
represent challenges for modern medicine [8]. The same above-mentioned microorganisms are able to colonize 
indwelling medical devices (IMD) like ocular/cochlear implants, orthopedic devices, catheters, and heart valves, 
providing the conversion from an acute infection to one that is persistent, chronic, and recurrent, most often requiring 
device removal in order to eliminate the infection [9]. Bacterial biofilms also underlie the persistent colonization of 
hospital facilities therefore driving and sustaining nosocomial infections, which place a billions of euros burden on the 
worldwide healthcare system annually [10]. Recently, microbial biofilms have been identified in a case of intra-
amniotic infection [11] and several scientists linked the presence of unwanted biofilm to Lyme disease, autism, and 
chronic immune dysfunction [12, 13]. The spread of recalcitrant infections is readily stated by the Centers for Disease 
Control and Prevention (CDC) and the National Institute of Health (NIH) that estimate 65-80 % of microbial infections 
currently treated by physicians in the developed world biofilm-mediated [4, 14, 15]. However, this percentage is 
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destined to increase as the scenario of biofilm-related diseases is continuously growing up as well as our concerns to 
loose powerful weapons against infectious diseases. 
Biofilm represents a surface-associated multicellular society embedded in a self-produced polymeric matrix and based 
on members that communicate with each other. Mounting evidence indicates that biofilm microorganisms undergo 
processes of cell specialization enabling coordinated and efficient survival strategies against the innate immune system 
and antimicrobial therapies [16]. The resistance of biofilms is clearly not caused by a single mechanism but by several 
factors acting in concert like diffusion limitation and non-genetic phenotypic heterogeneity [17-19]. Unsurprisingly, 
biofilm antibiotic susceptibility has been the subject of intense research and has been the focus of several excellent 
reviews [20-22].  
Thus, new antimicrobial-free strategies might be designed to reduce consumption of antimicrobial agents, ensuring the 
prudent use of these fragile strategies, protecting and empowering antibiotics that are critically important for human and 
animal health and wellbeing. The antibiotics that are available today are primarily variations on a single theme and 
focus on microbial eradication based on different modes of action at the molecular level. Some target cell-wall 
biosynthesis, whereas others inhibit protein synthesis or DNA replication. More recently, fatty-acid biosynthesis has 
been proposed as a viable bactericidal target [23]. Lysine analogues have also been identified that target lysine 
riboswitches and inhibit bacterial growth [24]. However, all these strategies shut down or subvert essential cellular 
functions that are crucial for microbial survival, promoting the development of drug-resistance.  
A new trend is to develop antibiofilm strategies functioning by mechanisms more subtle than the simple killing 
activities like those influencing the multicellular behavior, by manipulating the expression of specific phenotypes that 
represent microbial virulence traits (e.g. binding ability, motility, cell-to-cell communication, yeast–hyphae-
dimorphism) [25, 26]. This can be achieved by using a sub-lethal concentration of antibiofilm agents with novel targets, 
unique modes of action and proprieties that are different from those of the currently used antimicrobials. The rule is 
‘disarm microorganisms instead of killing them’, as depriving microorganisms of their virulence properties without 
threatening their existence offers a reduced selection pressure for drug-resistant mutations, providing compounds with 
longer shelf-lives [25, 27]. Observing the processes of biofilm formation it is reasonable to expect that interfering with 
the key-steps that orchestrate genesis of virtually every biofilm could be a way for new preventive strategies that do not 
necessarily exert lethal effects on cells but rather sabotage their propensity for a sessile lifestyle [26]. Three key steps 
are now considered promising targets for developing innovative antibiofilm strategies. The first step is to avoid 
microbial adhesion, interacting with the surface sensing process to repel pioneering cells keeping them in a planktonic 
form. The second step is the destruction of biofilm organization, mystifying intercellular and damaging the biofilm 
matrix destabilizing the physical integrity of the biofilms. Another interesting target is biofilm dispersal by forcing the 
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planktonic state, restoring the efficacy of antibiotics and the immune system [28, 29]. All these strategies are promising, 
as might be potentially used for co-dosing newly developed antibiofilm compounds that possess the above-mentioned 
characteristics with conventional antibiotics to eradicate biofilm-related infections. 
Natural products provide very interesting classes of biologically active, low-molecular-mass (< 5 kDa) compounds that 
possess a plethora of valuable biological activities far from killing activities (Table 1). In addition, natural products 
offer unmatched chemical diversity and such unexplored scaffolds represent promising new starting point to generate 
libraries of natural products analogs, which might have enhanced biological activities and drug-like properties (e.g. 
pharmacokinetics, solubility). Thus, organisms of terrestrial and marine origin are sources from which to draw 
inspiration for developing new antimicrobial-free antibiofilm strategies. We should keep in mind that the killing activity 
of natural compounds, like antibiotics, is a concentration-dependent process and primarily a laboratory property, since 
the levels of these agents available in nature would be insufficient to exert their lethal effects [26, 30, 31]. Currently 
used antimicrobial agents derived by screening natural products and compound libraries against whole organisms. The 
research myopia to see over a biocidal activity is limiting the recognition of new perspectives offered by sub-lethal 
concentrations of natural-derived compounds and their capacity to guide and improve the discovery, development and 
approval of innovative antimicrobial-free antibiofilm strategies. 
This review seeks to discern the scientific literature reporting natural compounds and their recent derivatives that 
possess the ability to modulate biofilm development through non-microbicidal mechanisms (sub-lethal concentrations) 
from their counterparts. The present work offers an overview about the approaches applied to the discovery of lead 
small molecules including i) conventional drug design methods like screening of chemical compounds obtained from 
nature and ii) computer-aided drug design approaches. Finally, a classification (not exhaustive but merely 
representative), based on the natural origin of small molecules and their synthetic derivatives was reported.  
 
Table 1: Partial list of nosocomial pathogens and small molecules from natural sources and their synthetic derivatives 
effective against biofilm associated diseases. 
Nosocomial 
pathogen 
Biofilm associated 
disease 
Active compounds Target Reference* 
Pseudomonas 
aeruginosa 
Cystic fibrosis lung 
infection, ventilator-
associated pneumonia, 
bacterial keratitis, 
otitis, burns, ischemic 
osteomyelitis  
Baicalein, Salicylic acid, 
nifuroxazide, chlorzoxazone, 
rosmarinic acid, naringin, 
chlorogenic acid, morin, 
mangiferin, furanones and their 
analogues 
QS 
 
 
42, 43, 46, 
61, 65, 66 
 
Methanolic extract of Capparis 
spinosa 
Motility and EPS 
production 
52 
TAGE, CAGE, Oroidin derivates 
 
Dispersion 68, 69, 70, 
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 73 
(Z)-2-decenoic acid Dispersion 100 
Acinetobacter 
baumannii 
Burn wound, trauma 
infection, ventilator-
associated pneumonia, 
meningitis, 
bacteremia, and 
urinary tract infections 
Dihydrosventrin and oroidin 
derivates 
QS and dispersion 71, 72, 74, 
75, 76, 77, 
78 
Ethyl N-(2-phenetyl) carbamate 
derivates 
Unknown 97 
Escherichia coli Urinary, 
gastrointestinal 
infection and 
septicemia 
Ursolic acid 
 
Chemotaxi and 
motility 
32 
 
Methanolic extract of Capparis 
spinosa 
 
Motility and EPS 
production 
52 
 
Furanones 
 
QS 63, 64 
Zosteric acid 
 
Motility, QS 26 
Oroidin derivates 
 
QS 79, 80 
Desformylflustrabromine 
derivates 
Unknown 94, 95 
Ethyl N-(2-phenetyl) carbamate 
derivates 
Unknown 98 
(Z)-2-decenoic acid Dispersion 100 
Staphylococci Burn wound, lung 
infection, sepsis, 
osteomyelitis and 
infections associated 
with foreign body 
material  
Esculetin and Fisetin QS 44 
Diterpenoid 7-(2-oxohexyl)-
taxodione 
Unknown 54 
Tannic acid 
 
Influenced 
bacterial cell 
surface 
hydrophobicity 
55 
 
Oroidin derivates 
 
QS 86 
Desformylflustrabromine 
derivates 
Unknown 95 
Guanidine and biguanide 
derivatives 
Unknown 99 
Streptococci  
 
Infections of 
respiratory tract, 
bloodstream and 
central nervous system 
Ellagic acid, Esculetin, Fisetin, 
Benzyl (6Z,9Z,12Z)-6,9,12-
octadecatrienoate, 3-benzyloxy-1-
nitro-butan-2-ol and 1,3 
cyclohexane dicarbohydrazide 
QS 
 
44, 50 
 
2-isopropyl-5-methyl-phenol 
 
Expression of the 
virulence genes 
gtfB, gtfC, brpA 
and spaP and EPS 
matrix 
48 
 
Epigallocatechin gallate, 
Melanoidine 
 
Attachment 
through 
suppression of gtf 
gene expression 
49, 51 
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Candida albicans Genital and catheter-
related bloodstream 
infections 
Zosteric acid Unknown 39 
Muscari comosum extract Dispersion 40 
(Z)-2-decenoic acid Dispersion 100 
Vibrio cholerae Nosocomial cholera Quinazoline-2,4-diamino 
analogue 
Motility 
 
35 
 
Analogues of mefloquine Unknown 36 
Stenotrophomonas 
maltophilia 
Respiratory, 
bloodstream, and 
urinary infections 
Emodin QS 45 
Serrantia 
marcescens 
Catheter-associated 
bacteremia, urinary 
tract infections and 
wound infections 
Methanolic extract of Capparis 
spinosa 
Motility and EPS 
production 
52 
Proteus mirabilis Urinary tract 
infections 
Methanolic extract of Capparis 
spinosa 
Motility and EPS 
production 
52 
 
(Z)-2-decenoic acid Dispersion 100 
Salmonella 
Typhimurium 
Gastrointestinal illness 7-methoxy-4-[4-(3-phenyl-2-
propen-1-yl)-1-piperazi-nyl]-5H-
pyrimido[5,4-b]indole 
Unknown 
 
37 
 
Oroidin derivates QS 83, 84, 86 
Klebsiella 
pneumoniae 
Pneumonia, 
bloodstream 
infections, meningitis, 
wound and surgical 
site infections 
(Z)-2-decenoic acid Dispersion 100 
* See the numbered reference in the text. 
 
SEARCH FOR NEW BIOFILM MODULATORS 
Recent technological advances and the development of new methods have revolutionized the screening of natural 
compounds and offer a unique opportunity to establish natural products as a major source of antibiofilm leads at sub-
lethal concentrations. At present, biochemical and cell-based assays are amenable to natural products screening with the 
possibility to couple them with high throughput screening (HTS) methods. Traditional and virtual HTS technologies are 
discussed in the following sections. 
 
High throughput technology for the screening of natural products 
Due to the scarcity of known molecular scaffolds able to modulate microbial biofilms at sub-lethal concentrations, HTS 
of compound libraries has been used as potent and valuable molecular tool for the identification of novel antibiofilm 
agents at sub-lethal concentrations. Thus, the workhorse platform for antibiofilm compounds discovery is an HTS 
approach using crude extract or small molecule compound libraries isolated from natural sources to identify candidates 
that mediate biofilm genesis. 
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Ren and colleagues [32] carried out pioneering work by screening 13,000 plant fractions with the final goal to identify 
novel small molecules that possess antibiofilm activity. They identified the promising compound Ursolic acid (1), (Fig. 
1) which effectively inhibited E. coli biofilm formation at concentrations as low as 22 μM without affecting growth. To 
investigate the mechanism of this non-toxic inhibition on a global genetic basis, DNA microarrays were used to study 
the gene expression profiles of E. coli grown with or without ursolic acid. Transcriptome analyses demonstrated that 
ursolic acid had no effects on the quorum-sensing systems autoinducer-1 (AI-1) and autoinducer-2 (AI-2), but it 
induced chemotaxis and motility genes in E. coli, suggesting that ursolic acid may function as a cue that tells cells to 
remain too motile for a proper biofilm formation [32]. Among the naturally occurring ursolic acid derivatives (general 
structure 2, Fig. 1), compound 3 showed antibiofilm activity at sub-lethal concentrations against the bacterial biofilm P. 
aeruginosa PA01, with an inhibition of 62% at 10 μg/ml [33]. 
 
Figure 1: Structures of Ursolic acid and derivatives. 
H
HO
COOHH
Ursolic acid (1)
HH
R2O
COOHH
                                              (2)
R1= H, OH
R2= H, cis-p-coumaroyl, trans-p-coumaroyl, trans-feruloyl
R3= H, OH
                                              (3) 
R1= H, 
R2 cis-p-coumaroyl, 
R3=OH
R1
R3
 
 
Junker and Clardy [34] developed a luminescence-based biofilm test for both attachment and detachment to identify 
small molecules that disrupt biofilm development by P. aeruginosa in an HTS format without the use of a lethal 
selection pressure. Among 66,095 molecules derived from libraries containing known bioactive compounds, natural 
products, and commercially available entities, 61 possessed notable activities against cell attachment and of these, 30 
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fell into six structural classes (general formulas of six structural classes 4-9 Fig. 2) as biofilm attachment inhibitors with 
EC50 of less than 20 μM. The active compounds and the general scaffold classes they represent do not have any known 
bacterial targets or mechanisms of action. However, the author speculated that the chemical nature of some of the 
compounds might lead them to be metal chelators.  
 
Figure 2: General formulas of the six structural classes. 
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An HTS of an 8,000-compound structurally diverse chemical library for small-molecule inhibitors of bacterial motility 
using Vibrio cholerae identified several compounds that inhibited motility without exhibiting toxicity [35]. The lead 
compound, a quinazoline-2,4-diamino analogue (10) (Fig. 3), showed inhibition of biofilm formation by 1.6 and 1.9-
fold at 18 h and 30 h respectively, at the sub-lethal concentration of 10 μg/ml. 
Recently, Peach et al. [36] developed high-throughput image-based 384-well format system for the identification of 
small molecule inhibitors of biofilm formation in V. cholerae. Application of this method led to the discovery of 29 
compounds many of which inhibited biofilm formation without altering bacterial cell viability. In particular, two lead 
compounds, which are analogues of the antimalarial drug mefloquine (11, 12) (Fig. 3), resulted effective by reducing in 
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biofilm coverage of 0.5 and 1.8% respectively (compared to coverage of 20% in untreated wells) with comparable 
bacterial growth to control wells. 
 
Figure 3: Structures of quinazoline-2,4-diammino analogue and mefloquine analogues. 
Q24DA (10)
N
N
NH
N
H
OH
N
HO
H2N
N
HO
Cl
(11)
(12)  
 
Robijns and co-workers [37] performed an HTS of 20,014 small molecules to search of non-toxic Salmonella biofilm 
inhibitors with a broad temperature activity. Out of the 20,014 compounds screened at 16 and 37 °C, 140 hits (0.7%) 
were identified. After characterization of the most promising hits at a broader set of temperatures, 7-methoxy-4-[4-(3-
phenyl-2-propen-1-yl)-1-piperazi-nyl]-5H-pyrimido[5,4-b]indole (13) (Fig. 4) was identified as an interesting 
preventive antibiofilm compound. Structure–activity relationship (SAR) studies indicated that the phenylpropenyl 
residue is essential for the activity of the compound, and the shortening of the linker between the phenyl and piperazinyl 
moiety, made the agent ineffective. The indole moiety, part of the pyrimidoindole scaffold, was determined as a second 
essential feature because removing or replacing the indole group abolished the antibiofilm activity. Also, methylation of 
the indole nitrogen rendered the compound inactive. Nonetheless certain substitutions at the R1, R2 or R3 position of 
the pyrimidoindole scaffold improved the activity. Structure-Activity Relationship (SAR) studies revealed 8-fluoro-4-
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[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]-5H-pyrimido [5,4-b]indole (14) (Fig. 4) a promising analogue in the 
prevention of Salmonella biofilm. 
 
Figure 4: Structures of indole derivatives. 
NH
N
N N N
R3
R1
R2
(13)  R1=OCH3, R2=R3=H
(14)  R1=R3=H, R2=F  
 
HTS of 42,865 compounds was performed to identify compounds that inhibit formation of Staphylococcus epidermidis 
RP62a biofilms without killing them [38]. After completing the three tiers (primary screening, hit confirmation, and 
dose-response curves), 352 compounds were selected as confirmed hit compounds from the HTS assay and among 
them, only 16 had an active concentration (AC50) lower than 10 µM. 
Despite the encouraging results, shortcomings of HTS have also been recognized and researchers begun looking at new 
methodological approaches for developing compounds better suited to become non-toxic antibiofilm compounds. 
Mounting evidences suggest that sub-lethal concentrations of naturally-derived compounds act in a concentration-
dependent manner, where upper and lower threshold concentrations trigger the formation of a biofilm, making the 
daunting task of developing new antimicrobial-free strategies even more challenging [39, 40]. Thus, if screening tests 
are conducted at appropriate concentrations, there is the possibility to obtain several orders of magnitude more 
compounds with the desired activity. In the context of antibiofilm researches, this means screening a wide range of sub-
lethal concentrations at frequent intervals in order to identify the experimental space with the maximum antibiofilm 
activity. However, the efforts of industrial, academic, governmental actors are made to reduce time and costs of 
research programs by testing few concentrations at standard conditions, demanding carefully designed experiments to 
explore in details and at reasonable cost the low-dose response and the cellular behavior in complex scenarios. 
Recently, Villa and colleagues [39, 40] successfully used the modeling tool Design of Experiment (DoE) to find the 
best working concentrations of plant-derived compounds just performing few experiments. The approach consists in 
defining a fixed range of variation for each variable (e.g. the variable concentration) then perform a series of 
experiments where all the variables vary within their respective ranges. When established a wide range of 
concentrations, the experiments are performed at the extreme points of the experimental region, which are most likely 
to be different from one another, and also the center-point to get information of what occurs inside the region. The 
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obtained dataset is analyzed by multivariate data analysis to obtain a polynomial equation predicting the performance of 
the compound under different conditions within the chosen domain. Thus, an area where a proper DoE set up could 
reduce the experimental workload is the optimization of biological assays in the multi-well framework for HTS. Novel 
experimental designs specifically developed to rationalize the design-making process are set up in a format that is 
compatible with the use of multi-pipettes and automated systems for preparation of multi-well plates [41]. The 
application of rational DoE could make the discovery of novel compounds more efficient and less time-consuming. 
 
In silico methods for virtual screening of natural products  
Computer-aided approaches are gaining popularity and have become an integral part of the drug discovery process in 
recent years. Virtual screening (VS) is increasingly used as a cost-effective complement to HTS and employs a range of 
methods to prioritize the selection and testing of large chemical datasets. This ensures that the most promising 
compounds are tested first in a lead discovery program. 
In the field of antibiofilm compounds, chemoinformatics approaches have not been fully exploited yet. The main 
drawback relies in the lacking of knowledge about molecular targets of the most promising antibiofilm compounds. 
However, a significant amount of available information from the scientific literature on antibiofilm compounds active at 
sub-lethal concentrations is tied to research involving the quorum sensing (QS), one particular form of cell-to-cell 
communication involving the production, release and detection of small signaling molecules (autoinducers). Computer-
aided drug design techniques, especially structure-based virtual screening (SB-VS), have also been employed in the 
search for new biofilm modulators. One such study involved the application of the automated docking program DOCK 
5.3.0 to screening for QS inhibitors of P. aeruginosa from a database containing 51 active components of Traditional 
Chinese Medicines (TCMs) with antibacterial activity [42]. By virtually determining if any of the target compounds 
exhibited similar docking characteristics to a known inhibitor of the Agrobacterium tumefaciens quorum sensing 
transcriptional regulator protein TraR, the authors hypothesized that hits in the virtual screen would translate into 
compounds also displaying antibiofilm activity against P. aeruginosa. The computer-based virtual screening revealed 
five potential QS inhibitors. The most active compound was Baicalein (15) (Fig. 5), which had no noticeable effect on 
bacterial growth. However, it significantly inhibited biofilm formation of the bacteria at a lower concentration of 20 
μM. Interestingly, Baicalein and ampicillin showed synergistic activity against P. aeruginosa. 
In a recent study, 147 recognized drugs and natural compounds were selected from the SuperNatural and SuperDrug 
databases on the basis of their two-dimensional (2D) structural similarity to the known quorum-sensing inhibitors 
furanone C30 (16), Patulin (17), the P. aeruginosa LasR natural ligand (3-oxo-C12-AHL (18)) and a known quorum-
sensing receptor agonist TP-1 (19) (Fig. 5) [43]. Six top-ranking drugs were acquired and tested for biological activity.  
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Figure 5: Structures of Baicalein, furanone C30, Patulin, 3-oxo-C12-AHL and TP-1. 
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This screen led to the discovery of three compounds, Salicylic acid (20), nifuroxazide (21), and chlorzoxazone (22) 
(Fig. 6), that showed significant inhibition of QS-regulated gene expression and related phenotypes at concentrations at 
which they did not affect bacterial growth. These compounds were also found to alter biofilm formation by P. 
aeruginosa PAO1. Treated biofilms were thinner and less structured than untreated ones and total biofilm mass was 
reduced in the presence of these quorum sensing inhibitors. 
The SB-VS was used for the identification of natural inhibitors of bacterial biofilm formation on a compilation of 
57,346 compounds from plants largely used in TCMs [44]. At the core of similarity-based virtual screening lies the 
resemblance between the reference structure and each of the structures in the compound library. The researchers found 
that Ellagic acid (23) (Fig. 7) (present in green tea) significantly inhibited biofilm formation of Streptococcus 
dysgalactiae. Based on Ellagic acid, they predicted a 2nd-generation list of compounds with similar characteristics. 
Compounds identified by virtual screening were subsequently selected for antibiofilm activity. Among them, Esculetin 
(24) (Fig. 7), proved to be the most efficient in preventing biofilm formation by S. aureus. To improve the efficacy and 
the range of affected organisms, a second round of virtual screening of Chinese Natural Product Database was 
performed using Esculetin as query. One of the predicted compounds, Fisetin (25) (Fig. 7), was even better to abolish 
biofilm formation than the two parent compounds preventing biofilm formation by S. dysgalactiae NCTC 4671 and 
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ATTC 27957 and S. aureus at 16 μg/ml. The secondary metabolites Esculetin and Fisetin significantly inhibited biofilm 
formation at concentrations at which they did not affect bacterial growth. 
 
Figure 6: Structures of Salicilyc acid, nifuroxazide and choloxazone. 
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Figure 7: Structures of Ellagic acid, Esculetin and Fisetin. 
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The DOCK 5.3.0 program was applied by Ding and colleagues [45] to screen for putative novel QS inhibitors of A. 
tumefaciens TraR from the database of compounds found in TCMs. Six out of 46 active components found in TCMs 
were identified as putative QS inhibitor based on docking scores. Of these, three compounds (26-28) (Fig. 8) inhibited 
biofilm formation by P. aeruginosa and Stenotrophomonas maltophilia at 200 µM, a concentration lower than the 
minimum inhibitory concentration (MIC). The fourth compound, emodin (29) (Fig. 8), significantly inhibited biofilm 
formation at 20 µM and induced proteolysis of the quorum-sensing signal receptor TraR in E. coli at a concentration of 
3–30 mM. Emodin also increased the activity of ampicillin against P. aeruginosa.  
 
Figure 8: Structures of Chrysophanol, Nodakenetin, Shikonin and Emodin. 
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OHOH O
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O OO
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Annapoorani and colleagues [46] applied the virtual screening program Glide version 5.5 to screen 1,920 natural 
compounds against two QS receptor proteins (LasR and RhlR) of P. aeruginosa. Based on the docking scores, five top 
ranking compounds namely rosmarinic acid (30), naringin (31), chlorogenic acid (32) (Fig. 9), morin (33) and 
mangiferin (34) (Fig. 10) were subjected to in vitro bioassays against laboratory strain PAO1 and two more antibiotic 
resistant clinical isolates, P. aeruginosa AS1 (GU447237) and P. aeruginosa AS2 (GU447238). All the five compounds 
were found to inhibit QS dependent virulence factors production and biofilm formation in both laboratory as well as 
clinical strains of P. aeruginosa without affecting growth. In addition, protein degradation assay clearly evidenced that 
the selected compounds did not degrade virulence enzymes, showing that inhibition is mediated through QS. 
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Figure 9: Structures of Rosmarinic acid and Naringin and Chlorogenic acid. 
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Figure 10: Structures of Morin and Mangiferin. 
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NATURAL PRODUCTS AND THEIR ANALOGUES 
Creation of libraries of crude extracts and/or compounds from plants and microorganisms is the typical process by 
which natural product samples are prepared and stored for screening purpose. However, the creation of a large library of 
complex mixture or individually isolated chemical compounds from natural products sources is a complex and costly 
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process, and it is not usually the exclusive approach taken by scientists engaged in the discovery of antimicrobial-free 
antibiofilm agents. In addition, in-silico screening is hindered by the lacking of knowledge about the molecular 
scaffolds able to modulate bacterial biofilms and the molecular targets of the most promising isolated antibiofilm 
compounds. 
Rather than employing conventional and virtual HTP screening programs, the exploration of smart terrestrial or marine 
metabolites on the basis of biologically and ecologically sound observations and experiments is gaining support [47]. 
For instance, the discovery of furanone compounds capable of inhibiting bacterial quorum-sensing systems isolated 
from the marine red alga Delisea pulchra, or 2-decenoic acid produced  during P. aeruginosa growth. Thus, 
biodiscovery programs based on sound biological rationales, or on the ethnobotanical data can provide a direct route to 
the discovery of useful non-toxic antibiofilm compounds. 
In addition, as the attention has now shifted to small high-quality libraries, natural product leads that possess antibiofilm 
activities at sub-lethal concentrations are legitimate starting templates for chemical manipulation to obtain analogues 
with increased activities. Novel biologically active analogs with potent and selective activities and improved 
solubilization and/or pharmacokinetic properties can be discovered and successfully used for the industrial scale up. 
This section is organized around structured class and origins of small molecules of natural origin and their synthetic 
derivatives, and it summarizes recent researches and highlights the advance in this field. Based on their origin, small 
molecules of natural origin and their synthetic derivatives can be grouped in: 
I) Plant extracts  
II) Marine products and derivatives 
a) halogenated furanones (HF) and their analogues. 
b) pyrrole-imidazole alkaloids.  
c) terpene derivatives. 
d)  indolic alkaloids derivatives 
III) Bacterial products and derivatives 
a) bacterial metabolites and their analogues. 
b) derivatives guanidinic and biguanidic from norspermidine.  
c) fatty acid messenger. 
 
I) Plant extract 
Extracts of Trachyspermum ammi (Ajowan) from the Apiaceae family are reported in literature for their antimicrobial 
and antioxidant properties. It was demonstrated their activity as bronchodilator in asthmatic patients and their analgesic 
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effect. Recently Khan et al. [48] analyzed the composition of the crude extract (CR) and its petroleum ether (PE) 
fraction by gas chromatography-mass spectrometry (GC-MS) and identified 2-isopropyl-5-methyl-phenol (34) (Fig. 11) 
as the main component of each extract (52.05% vs. 83.65%). The MIC determined for CR and PE was 320 µg/ml and 
40 µg/ml respectively on Streptococcus mutans ATCC 700610 involved in formation of dental bacterial plaque and 
recognized as responsible of cariogenicity effect on teeth. The reduction in the ability to form biofilm was dose 
dependent and did not affect S. mutans growth but only its aptitude to form biofilm. The authors proposed a mechanism 
of action that involved a modulation of the expression of specific virulence genes (gtfB, gtfC, brpA and spaP) by S. 
mutans and on the accumulation and structural organization of extracellular polysaccharides (EPS). Finally, a docking 
study was performed on models of four S. mutans proteins (Gtf B-C, BrpA and SpaP) to investigate their mode of 
interaction in presence of the 2-isopropyl-5-methyl-phenol. These results were helpful to design new drug candidates in 
order to inhibit virulence in S. mutans.  
Tea (infusion of dried leaves of Camelia sinensis) is the most popular beverage all over the world today. The 
polyphenolic components of this extract possess a large number of pharmacological properties such as antimicrobial, 
antidiabetic, anti-inflammatory. It was also demonstrated its anticariogenicity in humans and experimental animals [49]. 
The main component of black tea is Epigallocatechin gallate (EGCG) (35) (Fig. 11) that exhibited a wide range of 
pharmacological effects on S. mutans UA159 virulence factors related to its acidogenicity and acidurity. The EGCG 
inhibited biofilm formation at sub-lethal concentration (15.6 µg/ml) affecting the initial attachment of S. mutans to the 
surface through a mechanism that involved the suppression of gtf gene expression. It was demonstrated that this 
concentration was easily reached in oral cavity and did not influence the growth of oral bacteria. 
Salvadora persica is a desert plant miswak used in Saudi Arabia as a natural toothbrush. It was demonstrated that 
aqueous extract from this plant inhibited the growth of several microorganisms. In their work Murugan et al. [50] 
showed the antibiofilm activity of methanol, ethanol, chloroform, acetone and aqueous extracts. The methanolic ones 
was selected based on high activity on biofilm forming (87.92% inhibition) cariogenic isolate S. mutans SMS09 and 
then analyzed with GC-MS. Among the components identified, benzyl (6Z,9Z,12Z)-6,9,12-octadecatrienoate (36) (Fig. 
11), 3-benzyloxy-1-nitro-butan-2-ol (37) (Fig. 11) and 1,3 cyclohexane dicarbohydrazide (38) (Fig. 11) interfered with 
the QS. Their binding mode was investigated performing docking studies utilizing the crystal structure of quorum 
sensing response regulator (Luxr family) disposable in the Protein Data Bank (PDB ID:1NXO). This study 
demonstrated that extracts of S. persica might offer an interesting source of compounds able to reduce the dental caries 
inhibiting the initial adhesion and the following biofilm formation by cariogenic bacteria [50].  
Barley coffee (BC), derived from roasted barley, limits the adsorption of S. mutans on hydroxyapatite, the main 
constituent of surface teeth. The BC components were isolated through dialysis and gel filtration chromatography that 
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divided the low molecular mass fraction (polyphenols, zinc and fluoride ions) from the high molecular melanoidine 
mass fraction.  
The latter formed during the roasted process was devoid of antibacterial activities but displayed strong antiadhesion 
properties towards S. mutans ATCC25175. The antibiofilm activity of the high molecular mass fraction seemed to be 
related with the sucrose-dependent and -independent adhesion mechanism interfering with the enzyme Gtf and the QS 
system [51].  
Methanolic extract of Capparis spinosa showed an interesting activity on AHL mediated-quorum sensing in a dose 
dependent manner (0.5-2 mg/mL) without affecting bacterial growth of Serrantia marcescens FJ584421, E. coli 
ATCC10536, Proteus mirabilis ATCC7002 and P. aeruginosa PAO1. The extract was able to inhibit swimming and 
swarming motility of the bacterial patogens, EPS production and thus biofilm formation. One of the isolated 
components of the methanolic extract was homovanillic acid (39) (Fig. 11) that might possibly act as an analogue to the 
AHL molecule [52]. 
Sub-MIC concentration of extracts from the following Indian medicinal plants seemed to act as direct or indirect 
inhibitors of QS of P. aeruginosa PAO1: Hemidesmus indicus (L.) Schult (root), Holarrhena antidysenterica (Roth) 
A.DC. (bark), Mangifera indica (L.) (seed), Punica granatum L. (pericarp), and Psoralea corylifolia L. (seed) [53].  
An n-exane extract of Salvia austriaca hairy roots containing the diterpenoid 7-(2-oxohexyl)-taxodione (40) (Fig. 11) 
decreased adhesion of staphylococci to abiotic surfaces at 1.25-2.5 µg/ml concentration, which in turn caused a 
reduction in S. aureus ATCC29213 (MRSA methicillin – resistant strain) biofilm formation [54]. 
Tannic acid (41) (Fig. 12), the main component of the extract of Quercus infectoria G. Olivier nutgalls, a traditional 
Thai medicinal plant, showed the same MIC (0.13-0.50 mg/ml) of the whole extract against methicillin-resistant S. 
aureus suggesting that it might be the active component of the herb extract that influenced bacterial cell surface 
hydrophobicity that is involved in antibiofilm mechanisms. At sub-MIC only antibiofilm acitivity and not bacterial 
growth was inhibited [55].  
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Figure 11: Structures of Tymol, Epigallocatechin gallate, benzyl (6Z,9Z,12Z)-6,9,12-octadecatrienoate, 3-benzyloxy-1-
nitro-butan-2-ol, 1,3 cyclohexane dicarbohydrazide, homovanillic acid and 7-(2-oxohexyl)-taxodione. 
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Figure 12: Structure of tannic acid. 
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II) Marine products and derivatives 
a) Halogenated furanones (HFs) are small molecules (e.g. Compounds 42, 43) (Fig. 13) produced by the marine red 
algae Delisea pulchra, as defence mechanism, well known for their effect on bacterial QS [56, 57]. It is possible to 
evidence several structural similarities between HFs and AHLs such as the presence of a non-polar aliphatic carbon 
‘tail’ linked to a relatively polar ‘head’, besides to the most significant structural difference as the presence of bromine 
atoms. It has been shown that specific furanones affect several AHL-dependent activities through the binding with 
AHLs target receptors (LuxR protein homologues) favouring their degradation by proteolytic cleavage [58]. HFs were 
able to prevent biofilm formation and swarming in E. coli and B. subtilis [57,59] and they affected the expression of 93 
genes in P. aeruginosa [60]. 
 
Figure 13: Structures of natural halogenated furanones (a), synthetic halogenated furanones (b). 
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Some furanones, as 5-bromomethylene-5H-furan-2-one (44) (Fig. 13), lacking a side chain but bearing a vinyl bromide 
moiety, were able to penetrate P. aeruginosa biofilm and interfere with QS without any associated microbicidal 
properties [61]. Moreover, 44 showed activity against some Gram-positive oral Streptococcus biofilms. Particularly, it 
caused 63% and 76% reduction in biofilm growth, in polystyrene wells, of S. mutans and Streptococcus intermedius 
respectively, at 60 µM concentration [62].  
Starting from the natural furanone 43 (enhancing biofilm formation of S. epidermidis and S. aureus at concentration of 
10 to 20% of the MIC) [63], the influence of the number and the position of bromine atoms on the activity were 
explored. Compounds 45 and 46 at 224 µM concentration reduced E. coli biofilm formation by 75% and 63% 
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respectively, while the tetrabromo derivative 47 at 141 µM concentration caused a reduction of biofilm formation by 
80% [64]. Nevertheless, the other synthetic furanones 48-52, lacking bromine atoms but bearing an exocyclic ester, 
inhibited P. aeruginosa biofilm formation in flow cells confocal microscopy experiments (Fig. 13) [65]. By molecular 
modelling studies the binding energies of the synthetic furanones to the LasR receptor, compared with the known AHL 
signalling molecule 3-oxo-C12-AHL 18, were evaluated. Moreover docking studies highlighted that, in the binding 
pocket, the furanone scaffold overlapped with the lactone moiety of AHL, supporting the activity data. 
Recently, with the aim to target LasR and LuxR receptors simultaneously (multitarget approach) and to increase the 
potency of 3,4-dihalo-5H-furan-2-one by introduction of a substituted aromatic moiety, a set of 5-substituted 3,4-
dihalo-5H-furan-2-ones (erythro/threo 5-(aryl-1’-hydroxy-methyl)-3,4-dihalo-5H-furan-2-one 53a-53h and 5-(aryl-2-
methylene)- 3,4-dihalo-5H-furan-2.one 54a-b, 54f-i) (Fig. 14) were designed and synthesized. Their biofilm formation 
inhibitory activities against P. aeruginosa were studied by MIC assay, quantitative analysis of biofilm inhibition, and 
observation of biofilm formation with the scanning electron microscopy (SEM). Among these derivatives compound 
54i showed the best activity: 41.3%, 71.8% and 38.9% of biofilm formation inhibition against ATCC 27853, ATCC 
9027 and PAOA respectively, at 64 µM concentration. By molecular docking studies the binding mode between the 
inhibitors and the LasR receptor was identified. In contrast, the covalent linkage between the bromine atoms and the 
LuxS protein was not appropriate for the docking studies. The key structural features were the hydrogen bonds among 
the compound, the receptor protein and the aromatic ring substituted (especially with the hydroxyl group) as side chain. 
Therefore the highest potency of Z-54i could be related to the stabilization by hydrogen bonds and lipophilic electron-
donating aromatic ring (Fig. 14) [66]. 
b) Oroidin 55 and Bromoageliferin 56 are alkaloids produced by the marine sponge Agelasidae as chemical anti-feeding 
defence mechanism against predator [67]. They are structurally characterized by the presence of 2-aminoimidazole (2-
AI) subunits, the supposed key pharmacophore. 
The simplification of bromoageliferin structure led to the couple of analogues TAGE (trans- bromoageliferin) 57 and 
CAGE (cis-bromoageliferin) 58 showing a biofilm formation inhibition against P. aeruginosa PA01 and PA14. In 
details, TAGE inhibited PA01 and PA14 biofilm formation with IC50 values of 100 µM and 190 µM respectively, 
similarly to CAGE (IC50 values of 100 µM and 180 µM respectively) [68]. Moreover, TAGE was also able to disperse 
established P. aeruginosa biofilms with EC50 values of 82 µM and 114 µM against PA01 and PA14 respectively. The 
introduction of di-bromo substituted acylpyrrole moiety on TAGE scaffold (by analogy with bromoageliferin) led to 
several compounds including 59. 59 showed activity against P. aeruginosa PA01 and PA14 biofilm formation with IC50 
values of 1.77 µM and 12.0 µM respectively and against the mucoid variant isolated from patients affected by cystic 
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fibrosis with an IC50 value of 2.47 µM. Nevertheless, the acylated analogues were less efficient to disperse the pre-
formed P. aeruginosa biofilm in comparison with TAGE (Fig. 15)  [69]. 
 
Figure 14: Structures of 5-substituted 3,4-dihalo-5H-furan-2-ones (erythro/threo 5-(aryl-1’-hydroxy-methyl)-3,4-
dihalo-5H-furan-2-one) (a) and 5-(aryl-2-methylene)- 3,4-dihalo-5H-furan-2.one (b). 
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Figure 15: Structures of Orodin, Bromoageliferine and its derivatives. 
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Since Oroidin showed a similar activity to TAGE and CAGE on P. aeruginosa (IC50 values of 190 µM and 166 µM 
against PA01 and PA14 respectively) a 50-member library based on Oroidin scaffold/template was prepared [70]. The 
scaffold was divided into three sections: the AI-2 head group, the linker chain, and the pyrrole tail group and their 
modification were explored to define the structural requirements essential for the activity (Fig. 16). SAR analyses 
highlighted that the modifications to the 2-AI moiety led to inactive compounds. Nevertheless, the compound 60 
dihydrosventrin (DHS), an analogue of the natural alkaloid sventrin produced by the marine sponge Agelasidae, 
exhibited an antibiofilm activity against PA01, PA14, PD0300, A. baumannii and Bordatella bronchiseptica strain 
RB50 (with IC50 value of 51 µM, 111 µM, 115 µM, 110 µM and 238 µM) [71]. Belonging to the second-generation 
derivatives, compound 61, bearing a para-bromo phenyl substituent at nitrogen of the pyrrole ring, showed the highest 
activity against A. baumannii (IC50 value 27 µM and EC50 value 41 µM) (Fig. 16) [72]. 
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Figure 16: Structures of dihydrosventrin (DHS) and 2-AI derivatives. 
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Among the chemical modifications on the Oroidin template, also derivatives presenting the reversed amide bond were 
synthesized [73]. In particular, compounds bearing an aliphatic chain showed a low micromolar inhibition of biofilm 
development by PA01 and PA14 (better than Oroidin) and their potency was directly related to chain length. The most 
active compound, 62, exhibited the highest dispersion property (IC50 values 2.84 and 2.26 µM against PA01 and PA14 
EC50 values 33 and 21 µM against PA01 and PA14 respectively), although compound 63 showed an IC50 value of 729 
nM against PA14. The latter was grafted into a methacrylate polymer by a triazole linker, to develop new antibiofilm 
material for medical devices inhibiting the biofilm formation [74]. 
Moreover, the introduction of a triazole moiety on Oroidin scaffold was explored [75]. The most active 2-
aminoimidazole-triazole (2-AIT) obtained presented a triazole bearing, by an unsatured chain, an aryl group. In 
particular, compound 64 showed a broad spectrum inhibitory activity against both Gram-positive and Gram-negative 
bacteria (IC50 values of 5.6 µM, 530 nM, 980 nM and 810 nM against PA01 and PA14, A. baumannii and S. aureus 
respectively), dispersal properties, a synergistic effect with several antibiotics in the dispersion of pre-established 
biofilm of various bacterial strains, and re-sensitized planktonic bacteria of drug resistant strains of S. aureus and A. 
baumannii [76]. By introduction of substituents on phenyl ring, several dispersion agents against A. baumannii were 
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obtained and, in particular, 65 exhibited the best EC50 value (44.7 µM) respect to 64 (120 µM) [77]. The presence of 
further substituents on 2-AI moiety such as the phenyl ring led to a library of compounds and among them the most 
potent was 66 (Fig. 17) that showed an IC50 value of 1.42 µM against MRSA. Although 66 was less potent of the parent 
compound 64 against A. baumannii (IC50 value of 11.28 µM), it exhibited the property to disperse their pre-formed 
biofilm (EC50 values of 44.6 µM) [78]. 
The introduction of various alkyl-linked amides in substitution of the unsaturated aryl moiety led to the identification of 
compounds showing low micromolar biofilm inhibition against various Gram-positive and Gram-negative bacterial 
strains as well as fungal antibiofilm activity and dispersal property. The most interesting compounds presented para-
alkyl substituents on phenyl ring and the alkyl chain length modulated the activity. Although derivative 67 was the most 
active against MRSA (IC50 value of 0.7 µM and EC50 values of 0.9 µM), compound 68 inhibited biofilm formation by 
E. coli and a multi-drug resistant strain of A. baumannii with IC50 value of 11.2 µM and 1.9 µM respectively and EC50 
values of 23.4 µM and 7.9 µM. Furthermore 68 showed a high activity also against Gram-positive bacteria such as 
vancomycin-resistant enterococci (VRE) (IC50 value of 0.5 µM and EC50 values of 0.7 µM) and S. epidermidis (IC50 
value of 0.6 µM and EC50 values of 28.1 µM) [79, 80]. 
 
Figure 17: Structures of 2-AIT derivatives. 
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The replacement of the triazole by a substituted phenyl ring, directly bonded to 2-AI moiety, led to a 30-member 
library. Among them compound 69 inhibited E. coli biofilm formation with an IC50 value of 5.2 µM (Fig. 17) [81]. The 
parent compound 70, belonging to a related series of aryl 2-AI derivatives, showed a moderate activity against biofilm 
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formation by Salmonella Typhimurium (IC50 value of 130 µM at 25°C) and P. aeruginosa (IC50 value of 72.6 µM at 
25°C), while its para-chloro substituted derivative 71, the most active compound, inhibited biofilm formation by S. 
Typhimurium and P. aeruginosa with IC50 values of 16.0 µM and 3.5 at 25°C respectively (Fig. 18).  
The presence of alkyl substituents at 1-position of the 2-AI moiety (Fig. 18) tuned the activity: the derivatives bearing 
an intermediate length chain were most active against P. aeruginosa biofilm formation as compound 72 (IC50 value of 
2.6 µM) while longer alkyl chains led to compounds as 73-75 exhibiting activity against S. Typhimurium (IC50 values 
around 4 µM at 25°C) [82]. The introduction of a substituent also at position 2 of 2-AI ring led to a 2,4-disubstituted 2-
amino imidazole series and the most active compounds 76 and 77 showed antibiofilm activity against S. Typhimurium 
with IC50 values of 2.0 µM and 2.2 µM respectively and against P. aeruginosa with IC50 values of 0.9 µM and 0.7 µM 
respectively (Fig. 18)  [83]. 
 
Figure 18: Structures of 2-AI 4-phenyl substituted derivatives (a), 2-AI 5-substituted derivatives (b) and 2-substituted 
AI derivatives (c). 
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Among the 1,4,5-substituted series, the most active compounds 78 and 79 inhibited biofilm formation by S. 
Typhimurium with IC50 values of 10.3 µM and 18.3 µM respectively and by P.  aeruginosa with IC50 values of 27.4 
µM and 17.4 µM respectively (Fig. 19) [84]. 
The antibiofilm properties of scaffolds related to 2-AI were evaluated. Concerning the 2-aminobenzoimidazole (2-ABI) 
derivatives, the most active compound, 80, showed activity (possibly related to directly bind to Zn(II)) against the 
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biofilm formed by MRSA with IC50 value of 890 nM and EC50 value of 2.9 µM, by VRE with IC50 value of 1.4 µM and 
EC50 value of 75 µM, and by S. epidermidis with IC50 value of 570 nM and EC50 value of 7.3 µM [85]. 
Considering the pyrimidinium scaffold, among the series of 2-hydroxy-2-aryl-2,3- dihydroimidazo-pyrimidinium salts 
(intermediates in the synthesis of 2,4,5-trisubstituted 2-AI), compound 81 inhibited biofilm formation by S. 
Typhimurium with IC50 value of 1.7 µM and by P. aeruginosa with IC50 value of 4.2 µM [86]. Moreover, compound 82, 
belonging to a series of imidazo- [1,2α]pyrimidinium salts, showed antibiofilm formation activity against S. 
Typhimurium with an IC50 value of 1.5 µM and against P. aeruginosa with an IC50 value of 1.0 µM.  It has been 
suggested that activity of these compounds derived from their in vivo cleavage to the substituted 2-AI [82, 83].  
Also the 2-aminopyrimidine (2-AP) scaffold was investigated and the obtained derivatives exhibited a lower activity in 
comparison with 2-AI compounds (in particular against the Gram-negative bacteria) and were not able to disperse 
preformed biofilm. Among the most active derivatives, 83 inhibited biofilm formation by MRSA (with an IC50 value of 
72 µM) and 84 inhibited the formation of methicillin sensitive strain of S. aureus biofilm (with an IC50 value of 67 µM) 
(Fig. 19) [86].  
 
Figure 19: Structures of 1,4,5 substituted 2-AI derivatives (a), 2-ABI derivative (b), dihydroimidazo-pyrimidinium salts 
(c), 2-AP derivatives (d). 
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c) Among the diterpene alkaloids (Fig. 20), isolated as metabolites from the marine sponge Agelas nakamura, the 
adenine salts (structurally constituted by cyclic diterpene linked to 9-methyladeninium moiety), (-) Ageloxime D 85 (an 
oxime derivative) inhibited biofilm formation by S. epidermidis without interfering with the planktonic growth on the 
contrary of (-) Agelasine D 86, the corresponding amine (MIC < 0.0877 µM) [87-88]. 
 
Figure 20: Structure of (-)Ageloxime D and (-)Agelasine D. 
N
N
N N
H
+
H2NN
HN
N N
H
NHO
+
(-)Ageloxime D (85) (-)Agelasine D (86)  
 
Recently, a terpenoid-like library has been designed and a new class of 1,4-disubstituted-(1H)-1,2,3-triazole derivatives 
exhibiting antibiofilm activity identified. These compounds were obtained by the bioconjugation of natural terpenic 
framework (derived by linear diterpenes as Eleganolone 87 and Eleganediol 88 from the brown alga Bifurcaria 
bifurcata), meroditerpenes related to Geranylgeranyltoluquinol 89 (from the brown alga Halidrys siliquosa) and 3-(4’-
geranyloxy-3-methoxyphenyl)-2-trans propenoic acid 90 (from Acronychia baueri Schott)) (Fig. 21) and a synthetic 
moiety (related to the aromatic part of meroditerpenes), through a triazole linker via click chemistry methodologies. A 
first polyprenyl-type library (A) was constituted by 1,4-disubstituted triazoles 91 (Fig. 22) and these compounds were 
obtained as Z/E mixtures, while the second generation library (B) derivatives, presenting an oxygen bridge, were 
obtained as pure E-isomers 92, due to their easier preparation. By molecular modelling studies, performed on 4-
methoxy derivatives of each library, the comparison between the two libraries scaffolds highlighted that in the scaffold 
B the size of the triazolic linker, due to the presence of the oxygen bridge, is longer of 1.76 A, cLog(P) is lower and an 
additional H-bonding is located on the oxygen atom. SAR confirmed that, due to their similarities of the two series, the 
nature of the linker tune the activity without relevant variations in the biological response. The antibiofilm activity was 
evaluated against Pseudoalteromonas sp. strain and the most active compounds 92a and 10 92b, belonging to the library 
B, inhibited biofilm formation with EC50 values of 103 µM and 74 µM respectively (Fig. 22)  [89]. 
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Figure 21: Structures of Eleganolone, Eleganediol, Geranylgeranyltoluquinol and 3-(4’-geranyloxy-3-methoxyphenyl)-
2-trans propenoic acid. 
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Figure 22: Structures of 1,4-disubstituted triazole derivatives. 
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d) Flustramines are indole derived secondary metabolites [90, 91] produced by the bryozoan Flustra foliacea found in 
the northern Atlantic Ocean as chemical defence system, tuning the indole signaling pathway. Indole, along with AI-2, 
is considered a putative universal signal [92] since it is produced by 85 species of bacteria and it modulates biofilm 
formation [93], antibiotic resistance, virulence etc.  
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Flustramines is a family consisting of eleven secondary metabolites: six pyrroloindolines and five indolic alkaloids. 
Among the latter, Desformylflustrabromine (dFBr) 93 (Fig. 23) inhibited E. coli and S. aureus biofilm formation with 
IC50 values of 174 µM and 70 µM respectively, although by a toxic mechanism against E. coli  [94]. 
With the aim to identify non-toxic modulators of bacterial behaviour, considering dFBr as template, new indole 
derivatives were developed. The dFBr scaffold was subdivided into four areas (bromine region, prenyl group, indole 
nitrogen, aliphatic nitrogen region) and SAR studies were performed  [95]. The most potent analogue was 94 (Fig. 23) 
showing IC50 values of 5.9 µM and 53 µM against S. aureus and E. coli respectively [95]. Furthermore 94 is 10 - 1000 
times more active than indole itself to inhibit biofilm formation. 
 
Figure 23: Structures of Desformylflustrabromine and its derivative. 
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Recently, several interesting compounds, belonging to a pyrroloindoline triazole amide library (general formula 95) 
(Fig. 24), derived from Flustramine C and Dihydroflustramine C 96 (Fig. 14), have been identified as modulators of 
biofilm formation at low micromolar IC50 values against Gram-positive and Gram-negative bacteria strains [96]. 
 
Figure 24: General formula of pyrroloindoline triazole amide library and Dihydroflustramine C structure. 
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III) Bacterial products  
a) The bacterial metabolite, ethyl N-(2-phenetyl) carbamate 97 (Fig. 25) isolated from the cultured medium of the 
marine bacterium SCRC3P79 (Cytophaga sp.) showed a moderate biofilm formation inhibition of S. epidermidis 
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MRSA, VRE, MDRAB (multi-drug resistant A. baumannii) and E. coli. A library of analogues was synthesized 
obtaining compounds endowed with increased activity. Among them the most active were the menthyl derivatives 98-
100 (Fig. 25) inhibiting biofilm formation by S. aureus with IC50 values ranging from the mid to low molar [97]. 
In particular, compound 99 showed antibiofilm activity against MRSA (IC50 value of 4.87 µM) and E. coli (IC50 value 
of 34.6 µM) [98]. 
 
Figure 25: Structures of ethyl N-(2-phenetyl) carbamate and its menthyl derivatives. 
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b) Considering Norspermidine 101 (Fig. 26) (self-produced factor of B. subtilis), a natural key disruptor of the 
polymeric component of EPS, a focused library of biomimetic compounds, guanidine 102 and biguanide 103 
derivatives (Fig. 26) was developed. Some of these analogues exhibited 5-20 fold increased potency in preventing 
biofilm formation and >8 fold increased activity against respect to Norspermidine. In terms of minimum biofilm 
inhibitory concentration (MBIC), the most active inhibitors of biofilm formation were compounds 102a (2 µM) and 
102b (30 µM) against B. subtilis and compounds 102aa (55 µM) and 102b (20 µM) against S. aureus. By SAR a 
common structural motif useful to inhibit both biofilm species was identified, although the composition and structure of 
the two biofilms were different. Therefore the influence of the correct spacing of multiple amino or guanidine groups, 
during the binding of polyamine-based inhibitors with the exopolymer, was confirmed. In addition, studies on 
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protonation constants and crystal structure data revealed that the spacing of positively charged groups and the total 
charge at physiological pH played a determinant role in the antibiofilm activity [99]. 
 
Figure 26: Structures of Norspermidine (a) and its guanidine (b) and biguanide (c) derivatives. 
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c) (Z)-2-decenoic acid 104 (Fig. 27), produced by P. aeruginosa during growth, appeared to be functionally and 
structurally related to the class of short-chain fatty acid signalling molecules such as diffusible signal factor. Compound 
104 has also been identified as a potent biofilm-dispersion inducer, since, when added exogenously to P. aeruginosa 
PA01 microcolonies, it induced the complete biofilm dispersion at a native concentration of 2.5 nM. Moreover, 104 was 
shown to induce dispersion of biofilms formed by E. coli, K. pneumoniae, P. mirabilis, S. pyogenes, B. subtilis, S. 
aureus, and the yeast Candida albicans [100]. 
 
Figure 27: Structure of (Z)-2-decenoic acid. 
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CONCLUSION 
Healthcare-associated infections are a major problem that clinicians must deal with. Nowadays, the patient safety is 
seriously jeopardized by the emergence and spread of nosocomial pathogens in form of biofilm that are resistant to 
traditional and affordable antimicrobials. Considering that infectious disease is the second leading cause of death 
worldwide and that we are now entering the post-antibiotic era, limited treatment options for many nosocomial 
infections are available. In the light of the previously considerations, the development of novel antibiofilm compounds 
able to interfere, at sub-lethal doses, with the pathogenic biofilm cascade, represents an ideal preventive strategy to 
pursue. Depriving microorganisms of their virulence properties without affecting their existence may also apply a 
milder evolutionary pressure for the development of resistance, as most virulence traits are not essential for bacterial 
survival, restoring the efficacy of traditional antimicrobial agents. Thus, new antibiofilm templates with novel targets 
and unique mechanisms of action are urgently required. 
Nature has been proven to be an outstanding source for new and innovative antibiofilm compounds active at sub-lethal 
concentrations. Plants and microbes of terrestrial and marine origin are known to produce small molecules offering 
unmatched chemical diversity with structural complexity and biological potency. Some of these molecules exhibit novel 
biological activities that make them indispensable tools in biomedical research and unique prototypes for the 
development of innovative therapies.  
Now, the question is how to re-establish the leadership of natural products as a major source of leads for the 
development of antibiofilm compound active at sub-lethal concentrations. The first obstacle to overcome in the 
development of non-toxic antibiofilm agents is setting an appropriate screening method. Since biofilm formation is a 
very complex process, which is regulated by an interplay between many cellular systems, a ‘top-down’ approach, like 
screening for prevention of the biofilm as a whole, as compared to a target-based screening (‘bottom-up’), which 
depends on knowledge of biofilm targets already identified, is preferred. In addition, by subsequently studying the 
mode of action of potential biofilm modulators identified in a ‘top-down’ screening, possible new important biofilm 
targets can be identified providing the springboard to apply elegant computer-aided drug design approaches. Recently, 
the development of new technologies has revolutionized the screening of natural products offering a unique opportunity 
to re-establish natural products as a major source for antibiofilm compounds discovery. 
The diverse spectrum of biological activities these molecules possess in addition to their fascinating chemical structures 
makes them of particular interest for target-oriented synthesis. After identifying natural product leads, applying new 
synthetic methodologies would generate a large number of novels, structurally diverse analogs that can be screened for 
improved activities and properties at sub-lethal concentrations. We currently have the technology to prepare analogs 
and to explore the structure-activity relationships to truly harness the potential of these compounds.  
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Since the scientific community advances knowledge of how to discover, design and improve potent antibiofilm 
molecules, several issues emerge. First, we need to understand what are the exact mechanisms by which these 
molecules exert their effects at sub-lethal concentrations. Second, as with any drug development strategy, there still 
remain multiple technical challenges that need to be overcome before small molecule modulators can successfully 
transition into the clinic practice. Researchers will need to assess such parameters as compound toxicity, 
pharmacokinetics and pharmacodynamics, and validation in animal models. As a therapeutic strategy, these compounds 
will mostly likely serve as adjuvants to conventional antibiotics, and there are dosing and 
pharmacokinetic/pharmacodynamic issues that must be optimized between the antibiotic and antibiofilm agent. Third, 
new molecular classes should be investigated to expand our repertoire of antibiofilm agents. Fourth, various in vitro 
biofilm assays need to be compared to in vivo outcomes. Finally, further toxicity tests need to be established, especially 
with regards to the effects of antibiofilm compounds on commensal bacteria in their native host.  
The study of small molecules from natural products represents a cornerstone of medicinal chemistry and such 
compounds remain a fascinating group, not least because of the remarkable array of intriguing structures that continue 
to be isolated from almost every conceivable source showing antibiofilm activity at sub-lethal concentrations. However, 
much remains to be achieved as far as understanding how small molecules of natural origin are able to inhibit biofilm 
formation in diverse organisms and which are the compounds responsible of the activity. Despite these questions, it is 
exciting to imagine the potential of combinatorial therapy, such as the coupling of these molecules at sub-lethal doses 
with improved antibiotics, for more successful eradication of detrimental nosocomial infections. Future anti-infective 
treatments will most likely be comprised of combination therapies that produce additive or synergistic effects to target 
key processes in both the pathogen and the host. The overall promise of discovering novel antibiofilm compounds 
working at non-microbicidal manner has generated great hope in the biomedical community for discovery of new 
countermeasures against nosocomial infections. 
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